OVERVIEWPlease join us Wednesday February 27th at 10AM ET as we review the pharmaceutical industry's testimony before the Senate Finance Committee against the backdrop of proposed changes to manufacturer drug rebates. We will explore areas of agreement between the pharmaceutical industry's witnesses and the Trump Administration's proposed rule and what differences exist with Senate Democrats. Given areas of agreement, we will consider the realistic legislative initiatives that may develop in the coming months and how those might affect administration policy. We will evaluate likely outcomes, timing and impact on pharmacy benefit managers like CVS, insurers like UNH, ANTM, CI and HUM and the manufacturers like ABBV, MNK. Dial-in information will be available before the call or contact Sales@Hedgeye.com for access
|
Drug prices are a top priority on both sides of Capitol Hill and at the White House. Despite the divided government, there is broad agreement that action must be taken. The Senate Finance Committee held one hearing in January to which they invited executives from seven pharmaceutical companies. All declined to attend, to the great displeasure of Chairman Chuck Grassley and Ranking Member Ron Wyden. Another invitation was issued, this one with the thinly veiled threat of subpeona, which was all the inspiration executives from ABBV, AZN, BMY, JNJ, MRK, PFE needed to accept what promises to be a roastingon Tuesday.
We plan to be there and will review the testimony and how it might affect the Trump administration's efforts to eliminate drug rebates and what follow-on legislation might be under consideration. We will also discuss our latest prognostications on the rebate rule.
Please join us.
Emily Evans
Managing Director – Health Policy
Twitter
LinkedIn
